SG11201503783VA - Pyrimidine-2,4-diamine derivatives for treatment of cancer - Google Patents

Pyrimidine-2,4-diamine derivatives for treatment of cancer

Info

Publication number
SG11201503783VA
SG11201503783VA SG11201503783VA SG11201503783VA SG11201503783VA SG 11201503783V A SG11201503783V A SG 11201503783VA SG 11201503783V A SG11201503783V A SG 11201503783VA SG 11201503783V A SG11201503783V A SG 11201503783VA SG 11201503783V A SG11201503783V A SG 11201503783VA
Authority
SG
Singapore
Prior art keywords
pyrimidine
cancer
treatment
diamine derivatives
diamine
Prior art date
Application number
SG11201503783VA
Inventor
Martin Scobie
Thomas Helleday
Tobias Koolmeister
Sylvain Jacques
Matthieu Desroses
Marie-Caroline Jacques-Cordonnier
Original Assignee
Thomas Helledays Stiftelse För Medicinsk Forskning
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50828272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201503783V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thomas Helledays Stiftelse För Medicinsk Forskning filed Critical Thomas Helledays Stiftelse För Medicinsk Forskning
Publication of SG11201503783VA publication Critical patent/SG11201503783VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201503783VA 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer SG11201503783VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261797022P 2012-11-27 2012-11-27
SE1251332 2012-11-27
PCT/SE2013/051387 WO2014084778A1 (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer

Publications (1)

Publication Number Publication Date
SG11201503783VA true SG11201503783VA (en) 2015-06-29

Family

ID=50828272

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503783VA SG11201503783VA (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer

Country Status (20)

Country Link
US (3) US9604937B2 (en)
EP (1) EP2925744B1 (en)
JP (1) JP6322205B2 (en)
KR (1) KR102194646B1 (en)
CN (1) CN105143206B (en)
AU (1) AU2013353542B2 (en)
BR (1) BR112015011497B1 (en)
CA (1) CA2888338C (en)
CL (1) CL2015001437A1 (en)
HK (1) HK1216025A1 (en)
IL (1) IL238942B (en)
MX (1) MX2015006039A (en)
MY (1) MY182386A (en)
PE (1) PE20151412A1 (en)
PH (1) PH12015501058B1 (en)
PL (1) PL2925744T3 (en)
RU (1) RU2672916C2 (en)
SG (1) SG11201503783VA (en)
WO (1) WO2014084778A1 (en)
ZA (1) ZA201503470B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
KR102194646B1 (en) * 2012-11-27 2020-12-23 토마스 헬데이스 스티프텔스 퓌어 메디신스크 포르스닝 Pyrimidine-2,4-diamine derivatives for treatment of cancer
WO2015172747A1 (en) * 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
US10179790B2 (en) * 2014-06-04 2019-01-15 Thomas Helledays Stiftelse For Medicinsk Forskning MTH1 inhibitors for treatment of cancer
CN106794181A (en) * 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 MTH1 inhibitor for treating inflammatory and the LADA patient's condition
CA2952230C (en) * 2014-06-13 2023-03-21 Yuma Therapeutics, Inc. Pyrimidine compounds and methods using the same
CN104292213A (en) * 2014-09-08 2015-01-21 湖南华腾制药有限公司 Preparation method of pyrimidine derivative
JP6533997B2 (en) * 2014-12-26 2019-06-26 株式会社ヤクルト本社 Compound having ZNF143 inhibitory activity and use thereof
CN107207482A (en) 2015-02-13 2017-09-26 默克专利股份公司 Pyrimidine derivatives for treating cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016145383A1 (en) * 2015-03-11 2016-09-15 Board Of Regents, University Of Texas System Mth1 inhibitors for treating disease
CR20180323A (en) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd DERIVATIVES OF INDOL N-SUBSTITUTES AS MODULATORS OF PGE2 RECEIVERS
CN106928192B (en) * 2015-12-29 2020-11-13 中国科学院广州生物医药与健康研究院 Pyrimidine compound and preparation method and application thereof
CN105732516A (en) * 2016-03-09 2016-07-06 哈尔滨医科大学 Method for synthesizing MTH1 protein inhibitors TH287
US10981899B2 (en) 2016-04-28 2021-04-20 Cornell University Inhibitors of soluble adenylyl cyclase
KR101876514B1 (en) * 2016-11-08 2018-07-10 한국화학연구원 Novel pyrimidine compounds, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer and inflammation disease containing the same as an active ingredient
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
CN110621671A (en) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 Benzofuran and benzothiophene derivatives as PGE2 receptor modulators
KR102626982B1 (en) 2017-05-18 2024-01-18 이도르시아 파마슈티컬스 리미티드 Pyrimidine derivatives as PGE2 receptor modulators
AU2018269666B2 (en) 2017-05-18 2022-02-03 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
CN111065635B (en) * 2018-01-04 2022-07-22 无锡安万生物科技有限公司 Novel pyrimidine derivatives as MTH1 inhibitors
EP3759091A1 (en) 2018-03-01 2021-01-06 Thomas Helledays stiftelse för medicinsk forskning Substituted benzodiazoles and use thereof in therapy
CN113924085A (en) * 2019-04-12 2022-01-11 加利福尼亚大学董事会 Compositions and methods for increasing muscle mass and oxidative metabolism
US20220396567A1 (en) * 2019-09-30 2022-12-15 Hoffmann-La Roche Inc. Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection
CN110872291B (en) * 2019-11-26 2021-06-25 五邑大学 Tetrahydropyridopyrimidine compound and preparation method and application thereof
CN111557940A (en) * 2020-05-28 2020-08-21 青岛大学附属医院 Application of MTH1 inhibitor TH588 in preparation of medicine for treating multiple myeloma
GB202108249D0 (en) * 2021-06-09 2021-07-21 Univ Of Sussex Compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB681712A (en) * 1949-09-14 1952-10-29 Burroughs Wellcome Co Improvements in or relating to therapeutically useful pyrimidine compounds
US2691655A (en) * 1952-05-24 1954-10-12 Burroughs Wellcome Co 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same
EP0210228A1 (en) 1985-02-05 1987-02-04 The Upjohn Company 4-substituted-6-aryl pyrimidine compounds
US6169086B1 (en) 1997-01-27 2001-01-02 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
EP1103551A1 (en) * 1998-07-24 2001-05-30 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives and salts thereof
US20030208067A1 (en) 2001-05-30 2003-11-06 Cao Sheldon Xiaodong Inhibitors of protein kinase for the treatment of disease
WO2003015776A1 (en) 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
US7419984B2 (en) 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
WO2004080979A1 (en) * 2003-03-14 2004-09-23 Lg Life Sciences Ltd. Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives
WO2005026129A1 (en) 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
WO2005092899A1 (en) 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
WO2006078886A2 (en) 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
WO2009105220A1 (en) 2008-02-19 2009-08-27 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
US8268846B2 (en) * 2008-07-11 2012-09-18 Abbott Laboratories Amino heterocyclic linked pyrimidine derivatives
EP2362775B1 (en) * 2008-11-20 2015-08-05 GlaxoSmithKline LLC Chemical compounds
CN102711749A (en) * 2009-11-05 2012-10-03 莱西肯医药有限公司 Tryptophan hydroxylase inhibitors for the treatment of cancer
CA2789229A1 (en) * 2010-02-10 2011-08-18 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
GB201215502D0 (en) 2012-08-31 2012-10-17 Chalkiadakis Spyridon Medical use
KR102194646B1 (en) * 2012-11-27 2020-12-23 토마스 헬데이스 스티프텔스 퓌어 메디신스크 포르스닝 Pyrimidine-2,4-diamine derivatives for treatment of cancer

Also Published As

Publication number Publication date
US9944640B2 (en) 2018-04-17
HK1216025A1 (en) 2016-10-07
RU2672916C2 (en) 2018-11-21
US20180170929A1 (en) 2018-06-21
PH12015501058A1 (en) 2015-08-10
BR112015011497B1 (en) 2023-01-10
PE20151412A1 (en) 2015-10-10
BR112015011497A2 (en) 2017-07-11
US20170217961A1 (en) 2017-08-03
JP2016504289A (en) 2016-02-12
RU2015125458A (en) 2017-01-11
IL238942B (en) 2018-02-28
CA2888338C (en) 2021-07-20
PH12015501058B1 (en) 2015-08-10
EP2925744A1 (en) 2015-10-07
EP2925744B1 (en) 2020-12-30
MY182386A (en) 2021-01-22
US9604937B2 (en) 2017-03-28
PL2925744T3 (en) 2021-06-14
US20160002175A1 (en) 2016-01-07
EP2925744A4 (en) 2016-08-24
US10174029B2 (en) 2019-01-08
IL238942A0 (en) 2015-07-30
KR20150087271A (en) 2015-07-29
AU2013353542A1 (en) 2015-07-02
CN105143206B (en) 2019-01-15
JP6322205B2 (en) 2018-05-09
CL2015001437A1 (en) 2015-12-28
ZA201503470B (en) 2017-11-29
MX2015006039A (en) 2015-10-20
WO2014084778A1 (en) 2014-06-05
KR102194646B1 (en) 2020-12-23
AU2013353542B2 (en) 2018-04-05
CN105143206A (en) 2015-12-09
CA2888338A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
IL238942A0 (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
IL274318A (en) Treatment of cancer with tor kinase inhibitors
HK1206338A1 (en) Pyrimidine compounds for the treatment of cancer
HK1202247A1 (en) Treatment of cancer with tor kinase inhibitors tor
HK1201750A1 (en) Treatment of cancer with tor kinase inhibitors tor
HK1201753A1 (en) Treatment of cancer with tor kinase inhibitors tor
EP2925752A4 (en) Pyrimidine compounds for the treatment of cancer
HK1214128A1 (en) Treatment of cancer
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (en) Treatment of cancer
HK1205500A1 (en) Kinase inhibitors for the treatment of cancer
PL2855475T3 (en) Alpha-carbolines for the treatment of cancer
IL233493A (en) Imidazopyridine derivatives for the treatment of cancer
PT2925744T (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
IL237229A0 (en) Methods for treatment of cancer using lipoplatin
GB201217890D0 (en) Treatment of cancer
HK1202118A1 (en) Piperazinyl derivatives for the treatment of cancer
GB201208296D0 (en) Treatment of cancer